曲美他嗪联合卡维地洛治疗高血压性心脏病伴心力衰竭的效果及安全性  

The Efficacy and Safety of Trimetazidine Combined with Carvedilol in the Treatment of Hypertensive Heart Disease with Heart Failure

作　　者：李静 宋莉 王孝天 LI Jing;SONG Li;WANG Xiaotian(The First Affiliated Hospital of Bengbu Medical University,Bengbu 233000,China;不详)

机构地区：[1]蚌埠医科大学第一附属医院,安徽蚌埠233000

出　　处：《中外医学研究》2024年第34期59-62,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:研究曲美他嗪和卡维地洛治疗高血压性心脏病伴心力衰竭的效果及安全性。方法:回顾性分析2021年1月—2023年1月蚌埠医科大学第一附属医院收治的105例高血压性心脏病伴心力衰竭患者的临床资料。按照用药方式的差异,分为对照组50例和研究组55例,所有患者均使用正性肌力、扩毛细血管、利尿药和强心药等方法用药。对照组在此基础上使用卡维地洛片,研究组在对照组的使用基础上,加用盐酸曲美他嗪片治疗。两组患者均用药治疗半年。对比两组患者治疗前后的舒张压(DBP)、收缩压(SBP),左心室的射血分数(LVEF)、收缩末期容积(ESV)及舒张末期容积(EDV),心排出血量(CO)、每搏输出量(SV)及心率(HR),检测超敏C反应蛋白(hs-CRP)及血清B型钠尿肽(BNP)水平;评估患者进行6分钟步行实验(6MWT)水平。随访并记录两组患者1年内再次住院和由心血管疾病导致死亡的情况。结果:两组治疗后CO、SV、LVEF均上升,SBP、DBP、HR、ESV、EDV均降低;研究组CO、SV及LVEF高于对照组,SBP、DBP、HR、ESV、EDV低于对照组,差异有统计学意义(P<0.05)。两组治疗后hs-CRP及血清BNP均减少,6MWT距离增加;研究组hs-CRP及血清BNP低于对照组,6MWT距离长于对照组,差异有统计学意义(P<0.05)。两组1年内因心血管疾病导致的死亡率比较,差异无统计学意义(P>0.05),研究组半年、1年内再次住院率低于对照组,差异有统计学意义(P<0.05)。结论:曲美他嗪与卡维地洛联合治疗高血压性心脏病伴心力衰竭患者疗效明显,安全性高。Objective:To study the efficacy and safety of the combination of Trimetazidine and Carvedilol in the treatment of hypertensive heart disease with heart failure.Method:Retrospective study was conducted on the medical records of 105 patients with hypertensive heart disease and heart failure admitted to the First Affiliated Hospital of Bengbu Medical University from January 2021 to January 2023.According to the differences in medication methods,including 50 cases in the control group and 55 cases in the study group,all patients were treated with methods such as positive inotropic,dilated capillaries,diuretics,and cardiac stimulants.The control group used Carvedilol Tablets on this basis,while the study group added the drug Trimetazidine Hydrochloride Tablets to the treatment of the control group.Both groups of patients have been hospitalized for six months.The diastolic blood pressure(DBP),systolic blood pressure(SBP),left ventricular ejection fraction(LVEF),end systolic volume(ESV),and end diastolic volume(EDV),cardiac output(CO),stroke volume(SV),and heart rate(HR)before and after treatment between two groups of patients were compared.Detect the levels of high-sensitivity C-reactive protein(hs-CRP)and serum B-type natriuretic peptide(BNP);Conduct a 6-minute walking test(6MWT)on patients for evaluation.Follow-up and record the re-hospitalization and death caused by cardiovascular disease in two groups within one year.Result:After treatment,CO,SV and LVEF all increased,while SBP,DBP,HR,ESV and EDV all decreased,the CO,SV and LVEF of the study group were higher than those of the control group,while the SBP,DBP,HR,ESV and EDV of the study group were lower than those of the control group,the differences were statistically significant(P<0.05).After treatment,hs-CRP and serum BNP were decreased,and 6MWT distance was increased in both groups,the hs-CRP and serum BNP in the study group were lower than those in the control group,and the 6MWT distance was longer than that in the control group,the differences were statistical

关 键 词：高血压性心脏病 心力衰竭 卡维地洛 曲美他嗪 

分 类 号：R541.6[医药卫生—心血管疾病] R541.3[医药卫生—内科学]